Anti-clotting drug rivaroxaban wins FDA panel's support

03/19/2009 | NYTimes.com

A panel of FDA advisers endorsed the approval of rivaroxaban, an anti-coagulant by Johnson & Johnson and Bayer Healthcare Pharmaceuticals, as a preventive treatment for deep-vein thrombosis and pulmonary embolism in patients undergoing total knee- or hip-replacement surgery. The product could become an alternative to blockbuster drug warfarin if it gains final FDA clearance.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
UCare Minnesota
Minneapolis, MN
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Various Health Care and IT Positions
Centers for Medicare & Medicaid Services
Baltimore, Bethesda, MD
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Executive Vice President-MyHealth First Network
Greenville Health System
Greenville, SC